Norman Schwartz, MD
Family Medicine · Pataskala, OHNPI 1255322335
Payments from drug & device makers
Across 131 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393
- Bayer$228
- Sumitomo Pharma America, Inc.$196
- Sunovion Pharmaceuticals Inc.$147
- Pfizer$131
- Otsuka America Pharmaceutical, Inc.$120
- plus $998 from 24 others
What the payments were for
- Food & beverage$2,15697%
- Education$573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $393 |
| Bayer | 18 | $228 |
| Sumitomo Pharma America, Inc. | 11 | $196 |
| Sunovion Pharmaceuticals Inc. | 15 | $147 |
| Pfizer | 1 | $131 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Merck | 7 | $104 |
| Lundbeck LLC | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Indivior Inc. | 4 | $69 |
| AstraZeneca | 5 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $63 |
| Abbott | 3 | $48 |
| Amgen | 3 | $47 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Mylan Specialty L.p. | 2 | $44 |
| Smith+Nephew | 2 | $40 |
| Genentech USA, Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Lucid Diagnostics Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$131
How this compares
$2,213 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 59 | $66,573 |
| TrulicityDulaglutide | 43 | $44,041 |
| MounjaroTirzepatide | 29 | $33,051 |
| EliquisApixaban | 45 | $32,541 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $25,754 |
| OzempicSemaglutide | 22 | $22,590 |
| JanuviaSitagliptin Phosphate | 21 | $21,300 |
| OxycontinOxycodone Hcl | 12 | $20,026 |
| Spiriva HandihalerTiotropium Bromide | 20 | $19,096 |
| RybelsusSemaglutide | 14 | $17,131 |
| EntrestoSacubitril/Valsartan | 14 | $14,527 |
| JardianceEmpagliflozin | 20 | $12,040 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $9,179 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $8,514 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $44 | $77,09272 claims |
| AstraZenecaFarxiga, Symbicort | $67 | $71,78177 claims |
| Novo NordiskOzempic, Rybelsus | $15 | $39,72136 claims |
| PfizerEliquis | $131 | $32,54145 claims |
| MerckJanuvia | $104 | $21,30021 claims |
| NovartisEntresto | $45 | $14,52714 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $9,17960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Pataskala
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.